JP2017513906A - 炎症性腸疾患の治療に使用するための局所用組成物 - Google Patents

炎症性腸疾患の治療に使用するための局所用組成物 Download PDF

Info

Publication number
JP2017513906A
JP2017513906A JP2016564193A JP2016564193A JP2017513906A JP 2017513906 A JP2017513906 A JP 2017513906A JP 2016564193 A JP2016564193 A JP 2016564193A JP 2016564193 A JP2016564193 A JP 2016564193A JP 2017513906 A JP2017513906 A JP 2017513906A
Authority
JP
Japan
Prior art keywords
lactobacillus
composition
bifidobacterium
composition according
hyaluronic acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2016564193A
Other languages
English (en)
Japanese (ja)
Other versions
JP2017513906A5 (https=
Inventor
ビッフィ アンドレア
ビッフィ アンドレア
Original Assignee
ソファル ソシエタ ペル アチオニ
ソファル ソシエタ ペル アチオニ
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ソファル ソシエタ ペル アチオニ, ソファル ソシエタ ペル アチオニ filed Critical ソファル ソシエタ ペル アチオニ
Publication of JP2017513906A publication Critical patent/JP2017513906A/ja
Publication of JP2017513906A5 publication Critical patent/JP2017513906A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
    • A61K35/747—Lactobacilli, e.g. L. acidophilus or L. brevis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
    • A61K31/728—Hyaluronic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0031—Rectum, anus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Inorganic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Dermatology (AREA)
  • Biochemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2016564193A 2014-04-23 2015-04-22 炎症性腸疾患の治療に使用するための局所用組成物 Pending JP2017513906A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
ITMI2014A000751 2014-04-23
ITMI20140751 2014-04-23
PCT/IB2015/052938 WO2015162570A1 (en) 2014-04-23 2015-04-22 Topical composition for use in the treatment of inflammatory bowel disease

Publications (2)

Publication Number Publication Date
JP2017513906A true JP2017513906A (ja) 2017-06-01
JP2017513906A5 JP2017513906A5 (https=) 2018-06-07

Family

ID=50981755

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2016564193A Pending JP2017513906A (ja) 2014-04-23 2015-04-22 炎症性腸疾患の治療に使用するための局所用組成物

Country Status (6)

Country Link
US (2) US11464814B2 (https=)
EP (1) EP3134072A1 (https=)
JP (1) JP2017513906A (https=)
CA (1) CA2944118C (https=)
MA (1) MA39710A (https=)
WO (1) WO2015162570A1 (https=)

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2020533351A (ja) * 2017-09-12 2020-11-19 ソファー・エッセ・ピ・ア クロストリジウム・ディフィシル感染症の治療における新たな使用
JP2021505689A (ja) * 2017-12-06 2021-02-18 ラチドゥーエビオメ・エッセ・エッレ・エッレ プロバイオティクスに基づいた組成物及びその使用
JP2022102038A (ja) * 2020-12-25 2022-07-07 ライオン株式会社 ラクトフェリン含有固形製剤及びその用途
JP2022535875A (ja) * 2019-06-05 2022-08-10 ラック２バイオーム・ソチエタ・ア・レスポンサビリタ・リミタータ 細菌株ラクトバチルス・パラカゼイおよびヒアルロン酸を含む組成物および皮膚の治療のためのその使用
JP2023520081A (ja) * 2020-03-31 2023-05-15 セルバトゥス リミテッド 炎症性腸疾患に対する併用療法
KR102954284B1 (ko) 2019-06-07 2026-04-17 비바티스 파마 게엠베하 식물성 콘드로이틴 설페이트 및 히알루론산에 대한 식물성 출발 물질의 확인 및 선별, 및 식품, 보충제, 의료 기기 또는 약물에 사용되는 성분을 수득하기 위한 이러한 식물성 출발 물질의 변환

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ITMI20131467A1 (it) 2013-09-06 2015-03-07 Sofar Spa Uso di una composizione comprendente microrganismi per aumentare la produzione intestinale di acido butirrico, di acido folico o di niacina e/o per diminuire la produzione intestinale di acido succinico
MA39710A (fr) * 2014-04-23 2015-10-29 Sofar Spa Composition topique destinée à être utilisée dans le traitement d'une maladie inflammatoire de l'intestin
IT201600083376A1 (it) 2016-08-08 2018-02-08 Sofar Spa Uso di probiotici per aumentare l’assorbimento proteico
ITUA20164188A1 (it) 2016-06-08 2017-12-08 Sofar Spa Nuovo uso medico di probiotici
IT201600122724A1 (it) 2016-12-02 2018-06-02 Sofar Spa Exopolysaccharides and uses thereof
IT201600127498A1 (it) 2016-12-16 2018-06-16 Sofar Spa Probiotici per uso nella diverticolosi e malattia diverticolare
IT201600131819A1 (it) * 2016-12-28 2018-06-28 Metis Healthcare S R L Preparazione per spray orale
CN111973636A (zh) * 2019-05-21 2020-11-24 王飞 一种肛肠凝胶及其制备方法
US11751597B2 (en) 2019-11-05 2023-09-12 Alfasigma S.P.A. Compositions comprising bacterial strains for use in increasing the bioavailability of amino acids derived from proteins, and related food product methods and systems
KR102752058B1 (ko) 2023-08-25 2025-01-13 전남대학교 산학협력단 락토바실러스 루터리 nchbl-005 균주, 사균체 또는 이의 혼합물을 유효 성분으로 포함하는 염증성 질환 예방, 치료 또는 개선용 조성물
IT202300027471A1 (it) * 2023-12-20 2025-06-20 Beingpharma S R L Composizioni cosmetiche e collutori che le contengono per il benessere del cavo orale e dei denti
IT202300027477A1 (it) * 2023-12-20 2025-06-20 Beingpharma S R L Composizioni e collutori che le contengono per il trattamento di disturbi e patologie del cavo orale

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0517363A (ja) * 1991-07-11 1993-01-26 Yakult Honsha Co Ltd 抗炎症剤及びそれを含有する化粧料
RU2182008C1 (ru) * 2000-10-20 2002-05-10 Самойленко Игорь Иннокентьевич Вводимая перорально, ректально или интравагинально композиция, содержащая живые бактерии
US20110166100A1 (en) * 2010-01-04 2011-07-07 Wu Tsung-Chung Mixture of hyaluronic acid for treating and preventing inflammatory bowel disease

Family Cites Families (71)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5531989A (en) 1994-10-28 1996-07-02 Metagenics, Inc. Immunoglobulin and fiber-containing composition for human gastrointestinal health
CN1066926C (zh) 1996-04-08 2001-06-13 钟春燕 将椰子水发酵制作的食用纤维及其生产方法
US6461607B1 (en) 1998-08-24 2002-10-08 Ganeden Biotech, Inc. Probiotic, lactic acid-producing bacteria and uses thereof
CZ9900769A3 (cs) 1999-03-04 2000-10-11 Petr Ing. Drsc. Hušek Použití špičky s filtrem k vytvoření sloupce sorbentu s definovaným objemem v prostoru pod filtrem
US20020090416A1 (en) 1999-03-09 2002-07-11 Philip Connolly Method of enhancing absorption and utilization of protein
IT1307850B1 (it) 1999-03-15 2001-11-19 Italmed Di Galli Giovanna E Pa Composizione farmaceutica a base di fermenti lattici e carboidratinon assorbibili contenente un sale di calcio ed un sale di alluminio
EP1145643A1 (en) 2000-04-10 2001-10-17 Phillip Connolly Improved milk protein concentrate
US20040170617A1 (en) 2000-06-05 2004-09-02 Finegold Sydney M. Method of treating diseases associated with abnormal gastrointestinal flora
US20030092163A1 (en) 2001-07-26 2003-05-15 Collins John Kevin Probiotic bifidobacterium strains
FI20020078A7 (fi) 2002-01-15 2003-07-16 Danisco Immuunijärjestelmän stimulointi polydextroosilla
US6881419B2 (en) 2002-04-09 2005-04-19 William E. Lovett Vitamin formulation for enhancing bone strength
EP1539192A1 (en) * 2002-04-24 2005-06-15 Medicarb AB Composition and kit for the treatment of inflammatory bowel diseases
US7780970B2 (en) 2002-08-06 2010-08-24 Danisco A/S Composition
AU2002951270A0 (en) 2002-09-06 2002-09-19 Vri Biomedical Ltd Probiotic Bacterium and Methods of Use
WO2005001109A2 (en) 2003-05-06 2005-01-06 Government Of The United States Of America As Represented By The Sercretary Of The Department Of Health And Human Services National Institutes Of Health Methods and compositions to detect microbes in fecal samples
US20100112088A1 (en) 2003-08-29 2010-05-06 Jay Pravda Materials and methods for treatment of disorders associated with oxidative stress
AU2005217124A1 (en) 2004-02-27 2005-09-09 Stichting Laboratorium Voor Infectieziekten Method for detecting a microorganism in a fecal specimen
EP1722804B1 (en) * 2004-03-04 2015-01-21 E-L Management Corp. Skin treatment method with lactobacillus extract
US20090197249A1 (en) 2004-11-01 2009-08-06 George Mason University Compositions and methods for diagnosing colon disorders
EP2243383A3 (en) 2005-04-06 2011-02-16 Nestec S.A. A method and composition for nutritionally improving glucose control and insulin action
FI20051319L (fi) 2005-12-22 2007-06-23 Cyflo Oy Menetelmä eläimen ja/tai ihmisen ravitsemuksen ja hyvinvoinnin ja eläinten tuottavuuden seuraamiseksi ja kehittämiseksi
CN1840206A (zh) 2006-01-19 2006-10-04 上海交通大学 人源菌群仔猪模型的构建及仔猪肠道中菌群分子检测方法
EP1997886B1 (en) 2006-02-21 2013-06-05 National University Corporation University of Toyama Rapid method for identifying causative microorganism of infectious disease
CN101415731B (zh) * 2006-02-24 2011-11-02 丘比株式会社 新型低分子透明质酸和/或其盐以及使用其的化妆品、医药组合物和食品组合物
CA2689862A1 (en) 2006-06-09 2007-12-13 Nutravital Inc. Probiotic compositions comprising propionibacterium and uses thereof
US20080069861A1 (en) 2006-09-19 2008-03-20 National Starch And Chemical Investment Holding Corporation Probiotic/Non-Probiotic Combinations
US20080081035A1 (en) 2006-10-03 2008-04-03 National Enzyme Company Therapeutic protease compositions
US8460726B2 (en) 2006-12-18 2013-06-11 Advanced Bionutrition Corporation Dry food product containing live probiotic
EP1972208A1 (en) 2007-03-16 2008-09-24 Kirin Holdings Kabushiki Kaisha Composition for improving intestinal microflora
MX2009010187A (es) 2007-03-27 2009-10-19 Procter & Gamble Metodos y estuches para administracion de probioticos.
US8821928B2 (en) 2007-06-04 2014-09-02 Egalet Ltd. Controlled release pharmaceutical compositions for prolonged effect
WO2009008717A1 (en) 2007-07-06 2009-01-15 N.V. Nutricia Use of probiotics and fibers for diarrhoea
US8193155B2 (en) * 2009-02-09 2012-06-05 Elc Management, Llc Method and compositions for treating skin
US20090098088A1 (en) 2007-10-10 2009-04-16 The Procter & Gamble Company Methods And Kits For The Treatment Of Diverticular Conditions
CN101240315A (zh) 2008-02-21 2008-08-13 上海交通大学 检测药物防癌效果的非损伤性分子方法
EP2280713A1 (en) 2008-05-01 2011-02-09 The Procter & Gamble Company Methods and kits for the treatment of inflammatory bowel disorder conditions
WO2010008272A1 (en) 2008-07-15 2010-01-21 N.V. Nutricia Treatment of gut motility disorders
JP2010161944A (ja) 2009-01-13 2010-07-29 Syngen Biotech Co Ltd 新型カゼイ菌の亜種（ｓｇ９６）及びこれを含有する菌抑制組成物及びその用途
ES2778836T3 (es) 2009-03-05 2020-08-12 Probiotical Spa Cepas de bacterias que tienen una alta actividad antiinflamatoria
WO2010103132A1 (es) 2009-03-10 2010-09-16 Hero España, S.A. Aislamiento, identificación y caracterización de cepas con actividad probiótica a partir de heces de lactantes alimentados exclusivamente con leche materna
JP2013505289A (ja) * 2009-09-23 2013-02-14 トーマス・ジュリアス・ボロディ 腸管感染症の治療法
BR112012011294B1 (pt) 2009-11-12 2018-03-20 Nestec S.A. Composição nutricional para administração a um indivíduo
PL2515937T3 (pl) 2009-12-22 2020-05-18 Probi Ab Niesfermentowane kompozycje zawierające frakcję zbożową i probiotyk oraz ich zastosowania
ITUD20100112A1 (it) * 2010-06-09 2011-12-10 Farma Derma S R L Preparazione per uso vaginale e rettale e relativo procedimento di produzione
US11235008B2 (en) 2011-03-31 2022-02-01 Ganeden Biotech, Inc. Probiotic sports nutrition compositions
WO2012154738A1 (en) 2011-05-09 2012-11-15 The Cleveland Clinic Foundation Composition and method to improve intestinal health
GB201219873D0 (en) 2012-11-05 2012-12-19 Multigerm Uk Entpr Ltd Diverticulitis treatment
CN102919922A (zh) 2012-11-08 2013-02-13 黑龙江省轻工科学研究院 一种复合益生菌发酵蓝莓果汁粉的制备方法
CN105228635A (zh) 2013-03-05 2016-01-06 格罗宁根大学 Faecalibacterium prausnitzii HTF-F（DSM 26943）在抑制炎症中的应用
KR102250588B1 (ko) 2013-07-02 2021-05-12 오스트리아노바 싱가포르 피티이 리미티드 캡슐화 세포의 동결-건조 방법, 동결 건조된 캡슐화 세포, 동결 건조된 캡슐화 세포를 함유하는 조성물, 및 상기 세포 및 조성물의 용도
ITMI20131467A1 (it) 2013-09-06 2015-03-07 Sofar Spa Uso di una composizione comprendente microrganismi per aumentare la produzione intestinale di acido butirrico, di acido folico o di niacina e/o per diminuire la produzione intestinale di acido succinico
ITMI20131473A1 (it) 2013-09-06 2015-03-07 Sofar Spa Metodo per valutare gli effetti di una composizione comprendente microrganismi sul microbiota intestinale
MA39710A (fr) * 2014-04-23 2015-10-29 Sofar Spa Composition topique destinée à être utilisée dans le traitement d'une maladie inflammatoire de l'intestin
WO2015172191A1 (en) 2014-05-12 2015-11-19 Medlab Ip Pty Ltd Probiotic compositions and uses thereof for treatment of obesity-related disorders
DK2990045T3 (en) 2014-08-26 2017-02-13 Chr Hansen As Bifidobacterium animalis subsp. lactis for use in reducing abdominal pain in a postmenopausal woman
WO2017195182A1 (en) 2016-05-13 2017-11-16 Sofar S.P.A. Use of probiotics for improving protein absorption
IT201600083376A1 (it) 2016-08-08 2018-02-08 Sofar Spa Uso di probiotici per aumentare l’assorbimento proteico
ITUA20164188A1 (it) 2016-06-08 2017-12-08 Sofar Spa Nuovo uso medico di probiotici
IT201600122724A1 (it) 2016-12-02 2018-06-02 Sofar Spa Exopolysaccharides and uses thereof
ES2965306T3 (es) 2016-12-16 2024-04-12 Gervais Danone Sa Composición probiótica que comprende cepas de Lactobacillus rhamnosus y Lactobacillus paracasei
IT201600127498A1 (it) 2016-12-16 2018-06-16 Sofar Spa Probiotici per uso nella diverticolosi e malattia diverticolare
WO2019019961A1 (zh) 2017-07-26 2019-01-31 海思科医药集团股份有限公司 防治消化道和/或皮肤反应的菌群及其应用
IT201700101704A1 (it) 2017-09-12 2019-03-12 Sofar Spa Nuovo uso per trattamento delle infezioni da clostridium difficile
CN111511379B (zh) 2017-12-06 2024-06-18 Lac2生物群系有限公司 基于益生菌的组合物及其应用
CN108743851A (zh) 2018-08-09 2018-11-06 深圳市博奥生物科技有限公司 一种复合益生菌粉的制备方法及复合益生菌粉
IT201900016811A1 (it) 2019-09-20 2021-03-20 Sofar Spa Ceppi batterici, loro composizioni e loro uso per il trattamento di disturbi gastrointestinali
IT201900016850A1 (it) 2019-09-20 2021-03-20 Sofar Spa Composizioni a base di ceppi batterici e estratti di bacche e loro uso come antinfiammatori
IT201900016805A1 (it) 2019-09-20 2021-03-20 Sofar Spa Ceppi batterici, loro composizioni e loro uso per il trattamento di disturbi gastrointestinali
IT201900016865A1 (it) 2019-09-20 2021-03-20 Sofar Spa Composizioni a base di ceppi batterici e loro uso come antinfiammatori
US11751597B2 (en) 2019-11-05 2023-09-12 Alfasigma S.P.A. Compositions comprising bacterial strains for use in increasing the bioavailability of amino acids derived from proteins, and related food product methods and systems
IT201900020422A1 (it) 2019-11-05 2021-05-05 Sofar Spa Composizioni comprendenti ceppi di batteri per uso per aumentare la biodisponibilità degli amminoacidi derivanti da proteine

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0517363A (ja) * 1991-07-11 1993-01-26 Yakult Honsha Co Ltd 抗炎症剤及びそれを含有する化粧料
RU2182008C1 (ru) * 2000-10-20 2002-05-10 Самойленко Игорь Иннокентьевич Вводимая перорально, ректально или интравагинально композиция, содержащая живые бактерии
US20110166100A1 (en) * 2010-01-04 2011-07-07 Wu Tsung-Chung Mixture of hyaluronic acid for treating and preventing inflammatory bowel disease

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
ALIMENTARY PHARMACOLOGY AND THERAPEUTICS, vol. 35, JPN6019011006, 2012, pages 327 - 334, ISSN: 0004213121 *
DIGESTIVE DISEASES AND SCIENCES, vol. 56, JPN6019011008, 2011, pages 1178 - 1187, ISSN: 0004213122 *
FOOD STYLE 21, vol. 17, no. 6, JPN6020005640, 2013, pages 62 - 64, ISSN: 0004213124 *
UNITED EUROPEAN GASTROENTEROLOGY JOURNAL, vol. vol.1, Suppl.1, JPN6019011009, 2013, pages 219 - 325, ISSN: 0004213123 *
辨野 義己: "特集 プロバイオティクス機能研究の新展開", 食品工業 第５３巻第２号, vol. 第53巻, JPN6019011010, 2009, pages 44 - 51, ISSN: 0004005781 *

Cited By (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2020533351A (ja) * 2017-09-12 2020-11-19 ソファー・エッセ・ピ・ア クロストリジウム・ディフィシル感染症の治療における新たな使用
JP7387587B2 (ja) 2017-09-12 2023-11-28 ラチドゥーエビオメ・エッセ・エッレ・エッレ クロストリジウム・ディフィシル感染症の治療における新たな使用
JP2024003162A (ja) * 2017-09-12 2024-01-11 ラチドゥーエビオメ・エッセ・エッレ・エッレ クロストリジウム・ディフィシル感染症の治療における新たな使用
JP7801294B2 (ja) 2017-09-12 2026-01-16 ラチドゥーエビオメ・エッセ・エッレ・エッレ クロストリジウム・ディフィシル感染症の治療における新たな使用
JP2021505689A (ja) * 2017-12-06 2021-02-18 ラチドゥーエビオメ・エッセ・エッレ・エッレ プロバイオティクスに基づいた組成物及びその使用
JP2022535875A (ja) * 2019-06-05 2022-08-10 ラック２バイオーム・ソチエタ・ア・レスポンサビリタ・リミタータ 細菌株ラクトバチルス・パラカゼイおよびヒアルロン酸を含む組成物および皮膚の治療のためのその使用
JP7680376B2 (ja) 2019-06-05 2025-05-20 ラック２バイオーム・ソチエタ・ア・レスポンサビリタ・リミタータ 細菌株ラクトバチルス・パラカゼイおよびヒアルロン酸を含む組成物および皮膚の治療のためのその使用
KR102954284B1 (ko) 2019-06-07 2026-04-17 비바티스 파마 게엠베하 식물성 콘드로이틴 설페이트 및 히알루론산에 대한 식물성 출발 물질의 확인 및 선별, 및 식품, 보충제, 의료 기기 또는 약물에 사용되는 성분을 수득하기 위한 이러한 식물성 출발 물질의 변환
JP2023520081A (ja) * 2020-03-31 2023-05-15 セルバトゥス リミテッド 炎症性腸疾患に対する併用療法
JP2022102038A (ja) * 2020-12-25 2022-07-07 ライオン株式会社 ラクトフェリン含有固形製剤及びその用途
JP7718672B2 (ja) 2020-12-25 2025-08-05 日清食品株式会社 腸溶コーティング錠

Also Published As

Publication number Publication date
WO2015162570A1 (en) 2015-10-29
CA2944118A1 (en) 2015-10-29
US20170035816A1 (en) 2017-02-09
CA2944118C (en) 2020-06-30
EP3134072A1 (en) 2017-03-01
MA39710A (fr) 2015-10-29
US20230052820A1 (en) 2023-02-16
US11464814B2 (en) 2022-10-11

Similar Documents

Publication Publication Date Title
JP2017513906A (ja) 炎症性腸疾患の治療に使用するための局所用組成物
Liu et al. The microbiome in inflammatory bowel diseases: from pathogenesis to therapy
JP2022000040A (ja) 代謝障害を処置するための低温殺菌アッカーマンシアの使用
Alexandre et al. Probiotics: a new way to fight bacterial pulmonary infections?
Thompson et al. Minocycline and its impact on microbial dysbiosis in the skin and gastrointestinal tract of acne patients
Liu et al. Lactobacillus casei LH23 modulates the immune response and ameliorates DSS-induced colitis via suppressing JNK/p-38 signal pathways and enhancing histone H3K9 acetylation
Braat et al. A phase I trial with transgenic bacteria expressing interleukin-10 in Crohn’s disease
ES2437940T3 (es) Composición probiótica para uso en el tratamiento de la inflamación del intestino
US11896631B2 (en) Probiotics for use in the treatment of diverticulosis and diverticular disease
EP4272815A2 (en) New medical use of probiotics
Simeoli et al. Preventive and therapeutic effects of Lactobacillus paracasei B21060–based synbiotic treatment on gut inflammation and barrier integrity in colitic mice
JP7126004B2 (ja) 組成物及びその使用
JP2012040015A (ja) 食養生製品、食品添加物または医薬用アルカリ性スフィンゴミエリナーゼ含有組成物
CN102711778A (zh) 利用动物双歧杆菌细菌或含有这种细菌的发酵乳制品减轻胃肠炎症的方法
Kumar et al. Immunomodulatory effects of Bifidobacterium bifidum 231 on trinitrobenzenesulfonic acid-induced ulcerative colitis in rats
KR102827072B1 (ko) 장 부착능 향상 및 마이크로바이옴 변화를 유도하는 장기능 개선용 Lacto-5X 조성물
BR112019026963A2 (pt) composição compreendendo cepas bacterianas per-tencendo às espécies lactobacillus salivarius para o tratamento de mal de parkinson
JP2019501176A (ja) プロバイオティック組成物及びその使用
CN114040770B (zh) 用于治疗、缓和或预防痤疮的组合物
US9072768B2 (en) Composition and method for increasing effectiveness of radiation or chemotherapy
US20170273326A1 (en) Lactic acid bacteria-containing composition
Kanauchi et al. The therapeutic impact of manipulating microbiota in inflammatory bowel disease
CN101357142B (zh) 酪酸梭菌在制备防治心脑血管疾病药物组合物中的应用
JP7118594B2 (ja) 止瀉剤組成物
Aron et al. Probiotics and therapeutic effect in clinical practice–Review

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20161208

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20180417

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20180417

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20190402

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20190624

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20190823

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20191002

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20200218